Abstract

Knockdown of MTDH increases drug sensitivity to HDAC inhibitor and TRAIL combination treatment in endometrial cancer cells

Authors: Xiangbing Meng (University of Iowa) , Pavla Brachova (University of Iowa) , Shujie Yang (University of Iowa) , Zhi Xiong (University of Iowa) , Yuping Zhang (University of Iowa) , Kimberly K. Leslie (University of Iowa)

Abstract

Understanding the molecular mechanisms of chemoresistance is vital to design therapies to restore chemosensitivity. MTDH mediates drug resistance by regulating expression of genes required for the control of apoptosis and cell cycle. These findings indicate that sensitivity to chemotherapy agents and combination treatment with HDAC inhibitor and TRAIL can be restored by manipulating MTDH, and hence depletion of MTDH is a potentially novel avenue for effective cancer therapy.

Keywords: MTDH, Metadherin, TRAIL, LBH 589, HDAC

How to Cite: Meng, X. , Brachova, P. , Yang, S. , Xiong, Z. , Zhang, Y. & Leslie, K. K. (2011) “Knockdown of MTDH increases drug sensitivity to HDAC inhibitor and TRAIL combination treatment in endometrial cancer cells”, Proceedings in Obstetrics and Gynecology. 2(1). doi: https://doi.org/10.17077/2154-4751.1100